Central precocious puberty, or CPP, occurs when the hypothalamic-pituitary-gonadal axis is activated prematurely, leading to early breast development in girls and virilization in boys before the customary age. The condition matters clinically for more than cosmetic reasons: early activation of the axis accelerates skeletal maturation, can compromise final adult height, and may carry psychological and social consequences for children whose bodies mature years ahead of their peers. Over the past decade, loss-of-function mutations in MKRN3, an imprinted gene located in the Prader–Willi syndrome region of chromosome 15, have emerged as one of the most common genetic causes of familial CPP. Yet the same genomic neighborhood presents a paradox: when MKRN3 is deleted as part of the larger deletion that causes Prader–Willi syndrome, patients typically develop hypogonadism and delayed or incomplete puberty rather than precocious puberty. Because MKRN3 is paternally expressed and maternally imprinted, its loss through mutation removes an inhibitory brake on gonadotropin-releasing hormone secretion, hastening puberty, whereas the complex multi-gene deletion in Prader–Willi syndrome disrupts hypothalamic development in ways that blunt reproductive function.

The mechanistic basis for these opposing reproductive phenotypes has remained largely unclear. To address this, the team led by Yu-Yu Jin, Xiao Wang, Lin Yang, Jian Mu, and Fei-Hong Luo performed whole-exome sequencing on 98 Chinese children with central precocious puberty. They then carried out a systematic review of previously reported MKRN3 pathogenic and likely pathogenic variants to summarize genotype–phenotype correlations. Finally, they performed genome-wide DNA methylation profiling in CPP patients carrying the MKRN3 pathogenic variant and compared their methylation patterns with those of patients with Prader–Willi syndrome, patients with idiopathic central precocious puberty, and healthy controls. This three-pronged design allowed the investigators to move from variant discovery to clinical correlation to epigenetic characterization within a single cohort framework.

The sequencing effort identified a pathogenic frameshift variant, designated c.476dupC (p.Ala159fs*15), which introduces a duplication of a single cytosine base that shifts the reading frame and generates a premature stop codon. Notably, this is the first frameshift mutation reported within the inter-C3H1 hotspot region of MKRN3 in an Asian cohort, a finding that further confirms the functional significance of this segment of the protein. The MKRN3 protein carries multiple C3H-type zinc finger domains and a RING finger domain, and pathogenic variants have previously clustered in certain regions, making variant location an important clue to functional impact. The RING finger domain confers E3 ubiquitin ligase activity, meaning the protein tags other cellular proteins for degradation or modification, while the zinc finger domains mediate binding to RNA and protein targets. Frameshift variants that truncate the protein before these domains are complete are therefore expected to eliminate function almost entirely.

The genotype–phenotype analysis revealed a striking correlation between variant severity and clinical presentation. Patients carrying severe MKRN3 variants, such as frameshift or nonsense mutations predicted to truncate the protein, exhibited significantly earlier pubertal onset than those with missense mutations, beginning at a mean age of 5.80 years compared with 7.50 years (P = 0.029). The severity of the hormonal activation also differed: children with severe variants showed significantly higher luteinizing hormone peak levels during gonadotropin-releasing hormone stimulation testing, at 34.55 versus 11.00 IU/L (P = 0.047). These findings suggest that the degree of residual MKRN3 function, or the manner in which a truncated protein is produced and degraded, influences how vigorously the reproductive axis is disinhibited. In practical terms, the two-and-a-half-year difference in mean onset age between the variant classes is clinically meaningful, since earlier activation leaves a longer window of compromised growth potential and often requires more aggressive intervention with gonadotropin-releasing hormone agonist therapy to pause pubertal progression.

The most novel component of the study was the methylation analysis. DNA methylation, the addition of methyl groups to cytosine bases across the genome, is a key epigenetic mechanism that regulates gene expression without altering the underlying DNA sequence. Epigenetic regulation is known to be central to the timing of puberty: the reactivation of gonadotropin-releasing hormone secretion at the end of childhood is thought to depend on carefully orchestrated changes in chromatin state within hypothalamic neurons, and animal studies have shown that disrupting epigenetic machinery can shift pubertal timing substantially. MKRN3 itself has been implicated in epigenetic switching through its ubiquitination of MBD3, a component of chromatin-remodeling complexes. Given that MKRN3 sits in an imprinted genomic domain governed by methylation marks, the investigators asked whether MKRN3-associated CPP carries a distinct methylation signature.

Surprisingly, the analysis revealed no differences in methylation at the MKRN3 locus itself between the study groups. However, the comparison between MKRN3-CPP patients and Prader–Willi syndrome patients identified 18,609 differentially methylated positions across the genome, indicating that the two conditions, despite sharing the same chromosomal region, are epigenetically worlds apart. Key findings included pronounced hypermethylation of IGSF10 (a difference in methylation beta values of 0.37), ZC3H18 (0.27), SH3RF3 (0.36), and PTH1R (0.28) in the MKRN3-CPP group relative to PWS, alongside hypomethylation of MAGEL2 (−0.19) and PTPA (−0.23), where the delta-beta value represents the difference in DNA methylation beta values between the groups.

Several of these differentially methylated genes have plausible links to reproductive biology. IGSF10 is well established as a gene involved in the migration of gonadotropin-releasing hormone neurons during embryonic development, and mutations in it cause delayed puberty, making its epigenetic dysregulation particularly relevant to pubertal timing disorders. PTH1R, the parathyroid hormone 1 receptor, signals through the cAMP/protein kinase A pathway and is best known for its actions on bone. MAGEL2, which lies within the Prader–Willi syndrome critical region, is required for the production of secretory granules and neuropeptides in the hypothalamus, and its loss contributes to the impaired melanocortin pathway function characteristic of PWS. PTPA, a protein phosphatase 2A activator, has been shown to physically associate with the C-terminus of GPR54, the kisspeptin receptor that is a master gatekeeper of puberty, and has roles in osteoblast differentiation. SH3RF3 has been connected to the LIN28B pathway, which itself is among the genetic loci associated with age at menarche in large genome-wide association studies. Taken together, these targets trace a coherent map of the neuroendocrine and developmental circuits that determine when and how forcefully the reproductive axis awakens.

The authors propose that this pattern of differential methylation in downstream neuroendocrine pathways could potentially explain how divergent pubertal phenotypes arise in the setting of MKRN3 deficiency. In isolated MKRN3 mutations, the loss of the gene’s inhibitory action in kisspeptin-expressing neurons, together with its known role in modulating the stability and translation of GNRH1 messenger RNA through ubiquitination of poly(A)-binding proteins, removes the pubertal brake. In Prader–Willi syndrome, the methylation landscape of genes such as MAGEL2, a paternally expressed neighbor of MKRN3, is altered in the opposite direction, and the broader deletion disrupts neuropeptide production and hypothalamic circuitry, leading to insufficient rather than excessive gonadotropin secretion. The methylation data thus suggest that the clinical contrast between the two conditions may be inscribed in the epigenetic programming of shared downstream pathways rather than in MKRN3 itself. If confirmed, this would represent a conceptual shift: the direction of the pubertal phenotype would be determined not by the presence or absence of a single gene, but by the constellation of epigenetic states across the network it regulates.

The study has limitations worth noting. The methylation profiling was performed in peripheral blood samples, which may not fully reflect methylation states in the hypothalamic neurons that actually govern puberty, a common constraint in human neuroendocrine epigenetics. Blood-based methylation signatures can be confounded by differences in cell-type composition between patient groups, and tissue specificity remains a persistent challenge for the field. The cohort of MKRN3-mutant patients available for methylation comparison was necessarily small given the rarity of the condition, and the cross-sectional design cannot establish whether the methylation differences are causes or consequences of the divergent pubertal phenotypes. The researchers also note that the data were processed using beta-mixture quantile normalization to correct probe design bias in Illumina methylation arrays, and variant interpretation followed the American College of Medical Genetics and Genomics standards, but functional validation of the identified methylation changes will require further work, ideally in neuronal models or longitudinal cohorts.

Nevertheless, the implications are considerable. For clinicians, the genotype–phenotype correlation reinforces the value of molecular testing in children with central precocious puberty, particularly those with a family history or very early onset, and suggests that children with truncating MKRN3 variants may warrant particularly close attention to the pace of pubertal progression. Because MKRN3-related CPP is inherited in a pattern determined by the imprinting of the gene, molecular diagnosis also carries implications for genetic counseling of affected families, including the identification of relatives who carry the variant but may be asymptomatic. For researchers, the identification of an epigenetic signature distinguishing MKRN3-CPP from Prader–Willi syndrome opens a line of inquiry into how ubiquitin ligases and chromatin modifiers in the imprinted 15q11-q13 domain jointly sculpt the timing of human puberty. The work was supported by the National Natural Science Foundation of China and the Science and Technology Commission of Shanghai Municipality, and the data are available from the corresponding author on request.

More broadly, the study adds to a growing body of evidence that epigenetic marks can serve as interpretable intermediates between genetic lesions and complex developmental phenotypes. Just as methylation scores are being explored as predictors of metabolic disease risk, methylation profiling of pubertal disorders may eventually help stratify patients, refine prognosis, and illuminate therapeutic targets in the neuroendocrine circuitry that launches human reproduction. In an era when sequencing routinely uncovers rare variants of uncertain significance, studies that connect variant class, clinical severity, and epigenetic state provide exactly the kind of layered evidence needed to translate genomic findings into meaningful care for children whose puberty arrives, or fails to arrive, at the wrong time.

Premature adrenarche, defined by the early onset of adrenal androgen production before the age of eight in girls and nine in boys, defies straightforward interpretation due to its heterogeneous clinical presentations. Typically marked by the advancement of secondary sexual characteristics without the full activation of the hypothalamic-pituitary-gonadal axis, premature adrenarche has been linked to a spectrum of metabolic and endocrinological alterations. Central to understanding this condition is the evaluation of bone age, a biomarker reflecting skeletal maturation, which often appears accelerated in affected children.

Uli’s investigation underscores that while bone age advancement is a common finding in premature adrenarche, its clinical implications remain ambiguous. Bone age, estimated through sophisticated radiographic analysis of the hand and wrist, traditionally serves as a predictive tool for final adult height and pubertal timing. However, the heterogeneity of premature adrenarche renders bone age an unreliable solitary metric for forecasting these outcomes. This ambiguity prompts a reevaluation of existing diagnostic frameworks and suggests the necessity of integrating multifactorial assessments.

The study elucidates possible pathophysiological mechanisms driving bone age advancement in premature adrenarche, including early exposure to adrenal androgens. These hormones, particularly dehydroepiandrosterone sulfate (DHEAS), are known to accelerate epiphyseal maturation, the process by which the growth plates close. However, disparate androgen levels and varied tissue sensitivity among individuals complicate the clinical correlation. This individual variability challenges the binary interpretation of bone age as simply advanced or normal, demanding a more nuanced understanding of bone biology.

Crucially, Uli’s work emphasizes the interplay between premature adrenarche and metabolic disturbances such as insulin resistance and obesity. These comorbidities not only affect clinical presentation but may also influence bone maturation processes independently. For instance, hyperinsulinemia might promote bone growth through anabolic effects on osteoblasts, while obesity-related inflammatory mediators could disrupt normal growth plate function. Consequently, bone age advancement in these children may represent a multifactorial phenotype, where endocrine, metabolic, and genetic factors converge.

The paper further explores emerging diagnostic technologies that could enhance the precision of bone age estimation. Traditional Greulich and Pyle methods, though widely used, suffer from inter-observer variability and limitations in certain ethnic populations. Uli highlights advances in automated bone age assessment using machine learning algorithms, which offer promising improvements in accuracy and reproducibility. Such tools could become invaluable in dissecting the subtle skeletal changes observed in premature adrenarche, thereby aiding personalized clinical decision-making.

Another pivotal aspect of the research is the examination of longitudinal outcomes for children with early bone age advancement. Current evidence indicates that not all children with premature adrenarche and increased bone age experience compromised adult stature or early pubertal completion. Some may have a benign course with self-limited androgen excess, while others could develop polycystic ovary syndrome or other androgen excess states later in life. This prognostic uncertainty underscores the necessity for long-term monitoring and tailored management strategies.

In addressing treatment considerations, the study cautions against premature intervention aimed solely at normalizing bone age. Given the complex underpinning of bone maturation acceleration, therapeutic approaches should focus on mitigating associated metabolic risks rather than attempting direct modulation of skeletal development. Lifestyle interventions targeting obesity and insulin resistance may prove more beneficial and carry fewer risks than pharmacologic regimens, which remain ill-defined in this population.

Uli’s paper also invites a broader discourse on the implications of bone age advancement in pediatric endocrinology. Enhanced understanding of premature adrenarche’s skeletal manifestations could inform more accurate differentiation from central precocious puberty, a condition with different pathophysiology and treatment protocols. Such diagnostic clarity is vital, as misclassification can lead to either overtreatment or neglect of critical intervention windows.

Expanding the scope of research, the author recommends incorporating genetic and epigenetic analyses to elucidate individual susceptibilities influencing bone maturation timing. Variants in genes regulating adrenal steroidogenesis, growth plate physiology, or insulin signaling may confer differential risk profiles. Integrating these molecular insights with traditional radiographic assessments could revolutionize prognostic algorithms, paving the way for precision medicine in pediatric endocrinology.

Furthermore, the study touches upon psychosocial dimensions related to premature adrenarche and bone age advancement. Early physical maturation can affect psychological well-being, influencing self-esteem and social integration during critical developmental periods. Recognizing these aspects alongside physiological evaluation embodies a holistic approach essential for optimal patient care.

The translational potential of this research is immense, inviting collaborations among endocrinologists, radiologists, geneticists, and data scientists. Interdisciplinary efforts could harness big data analytics to refine bone age assessment models and identify phenotypic clusters within premature adrenarche cohorts. Such advancements promise not only improved diagnostic precision but also tailored therapeutic pathways enhancing outcomes.

In conclusion, N.K. Uli’s study represents a seminal contribution to the complex discourse surrounding premature adrenarche and bone age advancement. By revealing the multifactorial and enigmatic nature of skeletal maturation in this context, it challenges clinicians and researchers to adopt integrative perspectives. As technology and molecular insights advance, the hope is to transform interpretation from an ambiguous challenge into a streamlined, evidence-based practice that better serves the pediatric population.

This pioneering work heralds a new era in the pediatric endocrine evaluation, where bone age is contextualized within a broader matrix of endocrinological, metabolic, and genetic factors. Future research propelled by these insights is poised to unlock the full potential of early diagnosis and individualized care, ultimately enhancing lifelong health trajectories for children affected by premature adrenarche.

Subject of Research: Bone age advancement in premature adrenarche and its clinical interpretation challenges.

Article Title: Interpreting bone age advancement in premature adrenarche remains challenging.

Article References:
Uli, N.K. Interpreting bone age advancement in premature adrenarche remains challenging. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-04908-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-026-04908-6

Adipokines such as leptin, adiponectin, resistin, and others, have garnered substantial attention for their involvement in energy regulation, inflammation, and metabolic homeostasis, but their precise link to pubertal timing remains a subject of active investigation. By systematically evaluating circulating levels of these adipose-derived factors, the meta-analysis sheds light on potential biomarkers that could not only aid in the diagnosis but also enhance understanding of the pathophysiology of CPP. This comprehensive review bridges a critical gap in pediatric endocrinology, where the interplay between adipose tissue signaling and neuroendocrine maturation is still incompletely understood.

The significance of exploring adipokines in the context of early puberty extends beyond academic curiosity. The rising incidence of CPP globally, parallel with increasing childhood obesity rates, implies that adipose tissue—and the hormones it produces—may be key mediators linking energy balance with the initiation of reproductive maturity. Leptin, for example, is well-documented as a permissive factor for pubertal onset, communicating energy sufficiency to the hypothalamus. However, the full spectrum of how these molecules interact during abnormal pubertal timing scenarios such as CPP necessitates thorough integration of available data, precisely what this new meta-analysis achieves.

This systematic review meticulously combed through a large body of literature, extracting quantitative data from cohort studies, case-controls, and clinical observational research that assessed circulating levels of adipokines in girls diagnosed with CPP compared to age-matched healthy controls. Stringent inclusion criteria ensured that only studies using standardized assays and objective clinical criteria for CPP diagnosis were evaluated, thus enhancing the reliability of the findings. The meta-analytic approach allowed the researchers to consolidate heterogeneous data, increasing statistical power and enabling nuanced subgroup analyses.

One of the pivotal findings highlights that girls with CPP exhibit significantly elevated leptin levels compared to their healthy counterparts, supporting the concept that leptin acts as a critical neuroendocrine signal facilitating early puberty onset. The implications are twofold: first, leptin could serve as a predictive biomarker for early pubertal progression; second, it underscores leptin’s potential as a therapeutic target or a marker to monitor intervention efficacy in CPP management. Moreover, these elevations in leptin were observed independent of body mass index (BMI), suggesting a more direct regulatory role beyond simple fat mass correlation.

In contrast, the meta-analysis found that adiponectin, another major adipokine known for its insulin-sensitizing and anti-inflammatory properties, tends to be lower in girls with CPP compared to controls. This inverse relationship further accentuates the metabolic derangements associated with premature activation of the reproductive axis. Adiponectin’s diminution may reflect or contribute to a pro-inflammatory milieu that potentiates HPG axis stimulation, a hypothesis that invites further experimental exploration.

Additionally, resistin and visfatin, less commonly studied adipokines, were also evaluated, though the evidence was less robust. Trends toward higher resistin levels in CPP cases were noted, which aligns with resistin’s pro-inflammatory and insulin resistance-associated functions. However, due to limited data and variability among studies, definitive conclusions are precluded at this stage. This points to an important avenue for future research to expand the adipokine profile assessed in relation to precocious puberty and its metabolic sequelae.

Beyond mere association, the authors of the meta-analysis extensively discuss mechanistic pathways whereby adipokines may influence puberty timing. They consider leptin’s interaction with kisspeptin neurons, a critical stimulatory element of the HPG axis, and how altered adipokine balance could modulate hypothalamic sensitivity. The crosstalk between the adipose tissue-derived inflammatory signals and neuroendocrine regulators highlights a sophisticated, multilayered network that integrates environmental, metabolic, and genetic inputs to govern pubertal onset.

Importantly, the review underscores methodological heterogeneity and certain limitations across the included studies, such as variability in assay sensitivity, timing of blood sampling relative to pubertal staging, and differences in study populations including ethnic diversity and nutritional status. The authors advocate for standardized protocols in future research to enhance comparability and reproducibility, emphasizing longitudinal designs that can clarify causality rather than simple correlation.

From a clinical perspective, these findings have tangible implications. Identifying specific adipokine profiles linked to CPP could foster the development of blood-based diagnostic panels that complement clinical assessment, enabling earlier recognition and intervention. Moreover, understanding adipokine dynamics might also illuminate pathways that could be therapeutically modulated to delay or normalize premature pubertal progression, thus mitigating short- and long-term consequences including psychosocial stress and compromised adult height potential.

The interplay between obesity and CPP is complex and bidirectional; adipose tissue produces adipokines while excess adiposity can itself accelerate puberty. The meta-analysis carefully untangles these associations, suggesting that adipokine alterations in CPP are not simply a reflection of increased fat mass but may represent intrinsic pathological changes in adipose tissue function or adipokine signaling pathways intrinsic to early pubertal activation. This nuanced insight reframes the understanding of childhood obesity’s role in puberty, highlighting mechanistic subtleties beyond the traditional energy surplus hypothesis.

In conclusion, this systematic review and meta-analysis makes a compelling case that circulating adipokines are not just passive bystanders but active players in the neuroendocrine regulation of puberty. Girls with central precocious puberty exhibit a distinct adipokine signature characterized by elevated leptin and reduced adiponectin levels, with potential involvement of other adipokines that warrant further study. These patterns provide valuable clues to the biology of early puberty and open new vistas for diagnosis, monitoring, and perhaps even therapy.

The research community now faces the exciting challenge of translating these insights into practical clinical tools and interventions. Integrative studies combining molecular, genetic, and metabolic data in diverse populations will be crucial to refining the understanding of adipokine-mediated mechanisms governing pubertal timing. As this field evolves, it holds promise not only for managing CPP but also for broader metabolic and reproductive health conditions rooted in developmental endocrinology.

Ultimately, appreciating the multifaceted role of adipose tissue hormones in puberty underscores the intricate connectivity between metabolism and reproduction. These findings remind us that age-old biological milestones like puberty are governed by a dynamic interplay of systemic signals, many of which are still being unraveled. This meta-analysis represents a significant leap forward, illuminating the adipokine landscape in the context of one of pediatric endocrinology’s most challenging disorders, central precocious puberty.

Subject of Research:

Circulating adipokine levels in girls with central precocious puberty compared to healthy controls.

Article Title:

Circulating adipokines in girls with central precocious puberty: A systematic review and meta-analysis.

Article References:

Jiang, M., Gao, Y. & Huang, L. Circulating adipokines in girls with central precocious puberty: A systematic review and meta-analysis. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-03976-4

Image Credits:

AI Generated

DOI:

https://doi.org/10.1038/s41390-025-03976-4